Drug resistance in leishmaniasis
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60 years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb(v)). Widespread misuse has led to the emergence of Sb(v) resistance in the hyperendemic areas of North Bihar. Other antileishmanials could also face the same fate, especially in the anthroponotic cycle. The HIV/ visceral leishmaniasis (VL) coinfected patients are another potential source for the emergence of drug resistance. At present no molecular markers of resistance are available and the only reliable method for monitoring resistance of isolates is the technically demanding in vitro amastigote-macrophage model. As the armametrium of drugs for leishmaniasis is limited, it is important that effective monitoring of drug use and response should be done to prevent the spread of resistance. Regimens of simultaneous or sequential combinations should be seriously considered to limit the emergence of resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“[58] The PGPA gene has been shown to be frequently amplified in Leishmania cells that are selected for resistance to arsenite-or antimony-containing drugs.”
METABOLISM AND FUNCTIONS OF TRYPANOTHIONE IN THE KINETOPLASTIDA
Fairlamb, A. H., & Cerami, A. (1992) · Annual Review of Microbiology · doi:10.1146/annurev.mi.46.100192.003403 · Cited by 768
Leishmania and human immunodeficiency virus coinfection: the first 10 years
Alvar, J., Cañavate, C., Gutiérrez-Solar, B., Jiménez, M., Laguna, F., López-Vélez, R., Molina, R., & Moreno, J. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.2.298 · Cited by 736
Sundar, S., More, D. K., Singh, M. K., Singh, V. P., Sharma, S., Makharia, A., Kumar, P. C. K., & Murray, H. W. (2000) · Clinical Infectious Diseases · doi:10.1086/318121 · Cited by 664
Self-citationInjectable Paromomycin for Visceral Leishmaniasis in India
Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., & Bhattacharya, S. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066536 · Cited by 471
Self-citationLeishmania/HIV co-infections: epidemiology in Europe
Desjeux, P., & Alvar, J. (2003) · Annals of Tropical Medicine & Parasitology · doi:10.1179/000349803225002499 · Cited by 398
Miltefosine for New World Cutaneous Leishmaniasis
Soto, J., Arana, B. A., Toledo, J., Rizzo, N., Vega, J. C., Diaz, A., Luz, M., Gutierrez, P., Arboleda, M., Berman, J. D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/383321 · Cited by 385
Croft, S., & Yardley, V. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396258 · Cited by 380
Pentamidine uptake and resistance in pathogenic protozoa: past, present and future
Bray, P. G., Barrett, M. P., Ward, S. A., & de Koning, H. P. (2003) · Trends in Parasitology · doi:10.1016/s1471-4922(03)00069-2 · Cited by 261
The Leishmania ATP-binding Cassette Protein PGPA Is an Intracellular Metal-Thiol Transporter ATPase
Légaré, D., Richard, D., Mukhopadhyay, R., Stierhof, Y.-D., Rosen, B. P., Haimeur, A., Papadopoulou, B., & Ouellette, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102351200 · Cited by 242
Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania.
Mukhopadhyay, R., Dey, S., Xu, N., Gage, D., Lightbody, J., Ouellette, M., & Rosen, B. P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10383 · Cited by 238
Epidemiology of visceral leishmaniasis in India.
Bora, D. (1999) · PubMed · Cited by 236
Heavy metal resistance: a new role for P-glycoproteins in Leishmania.
Callahan, H. L., & Beverley, S. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55077-8 · Cited by 226
Sundar, S., Rai, M., Chakravarty, J., Agarwal, D., Agrawal, N., Vaillant, M., Olliaro, P., & Murray, H. W. (2008) · Clinical Infectious Diseases · doi:10.1086/591972 · Cited by 209
Self-citationHuman leishmaniases: epidemiology and public health aspects.
Desjeux, P. M. P. (1992) · PubMed · Cited by 198
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial
(1994) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068903 · Cited by 195
Grondin, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.3057 · Cited by 188
Berman, J. D., Badaró, R. J. D. S., Thakur, C. P., Wasunna, K. M., Behbehani, K., Davidson, R. N., Kuzoe, F. A. S., Pang, L. W., Weerasuriya, K., & Bryceson, A. D. M. (1998) · Europe PMC (PubMed Central) · Cited by 171
Sudhandiran, G., & Shaha, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301975200 · Cited by 168
Zhou, Y., Messier, N., Ouellette, M., Rosen, B. P., & Mukhopadhyay, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404383200 · Cited by 161
Pharmacokinetics and pharmacology of terbinafine and itraconazole
Leyden, J. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70483-9 · Cited by 129
Thakur, C. P., Kumar, M., Kumar, P., Mishra, B. N., & Pandey, A. K. (1988) · BMJ · doi:10.1136/bmj.296.6636.1557 · Cited by 99
Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
Sundar, S., Jha, T. K., Thakur, C. P., Mishra, M., Singh, V., & Buffels, R. (2002) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2002.66.143 · Cited by 98
Self-citationDrug resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania
Ouellette, M., & Borst, P. (1991) · Research in Microbiology · doi:10.1016/0923-2508(91)90089-s · Cited by 97
Russo, R., Nigro, L., Minniti, S., Montineri, A., Gradoni, L., Caldeira, L., & Davidson, R. N. (1996) · Journal of Infection · doi:10.1016/s0163-4453(96)91343-2 · Cited by 94
Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial.
Sn, J., Singh, N. K., & Tk, J. (1991) · PubMed · Cited by 85
ABC transporters in Leishmania and their role in drug resistance
Ouellette, M., Légaré, D., Haimeur, A., Grondin, K., Roy, G., Brochu, C., & Papadopoulou, B. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80213-6 · Cited by 83
Comparison of regimens of treatment with sodium stibogluconate in kala-azar.
Thakur, C. P., Kumar, M., Singh, S. K., Sharma, D., Prasad, U., Singh, R. S., Dhawan, P. S., & Achari, V. (1984) · BMJ · doi:10.1136/bmj.288.6421.895 · Cited by 73
Laguna, F., Videla, S., Me, J.-M., Sirera, G., Torre-Cisneros, J., Ribera, E., Prados, D., Clotet, B., Sust, M., López-Vélez, R., et al. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg356 · Cited by 72
Giorgio, C. D., Faraut-Gambarelli, F., Imbert, A., Minodier, P., Gasquet, M., & Dumon, H. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.1.71 · Cited by 63
Carson, P. E. (1984) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-69254-3_3 · Cited by 17
[Childhood Mediterranean visceral leishmaniasis].
Cascio, A., & Colomba, C. (2003) · PubMed · Cited by 15
Cited by
Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
Haldar, A. K., Sen, P., & Roy, S. (2011) · Molecular Biology International · doi:10.4061/2011/571242 · Cited by 408
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis
Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., Chennamaneni, N. K., Pendem, N., Buckner, F. S., Gelb, M. H., et al. (2014) · Chemical Reviews · doi:10.1021/cr500365f · Cited by 348
Possibilities and challenges for developing a successful vaccine for leishmaniasis
Srivastava, S., Shankar, P., Mishra, J., & Singh, S. (2016) · Parasites & Vectors · doi:10.1186/s13071-016-1553-y · Cited by 201
Metadata
- Authors
- Chakravarty, J., & Sundar, S.
- Venue
- Journal of Global Infectious Diseases
- Publisher
- Medknow
- Published
- 2010
- Volume
- 2
- Issue
- 2
- Pages
- 167
- ISSN
- 0974-777X (ISSN-L)
- OpenAlex
- W2114457715
- Cited by
- 270
- References
- 32
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.